🇺🇸 FDA
Patent

US 10308658

Salt of EGFR inhibitor, crystalline form and uses thereof

granted A61KA61K2300/00A61K31/337

Quick answer

US patent 10308658 (Salt of EGFR inhibitor, crystalline form and uses thereof) held by SUNSHINE LAKE PHARMA CO., LTD. expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
SUNSHINE LAKE PHARMA CO., LTD.
Grant date
Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2300/00, A61K31/337, A61K31/427, A61K31/436